(SEAL) Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

The PI of this project was: Keith Meyer, MD

This project was funded by: Bristol-Myers Squibb

The term of this project was: March 2015 to December 2017

The number of subjects scanned during this project was: 30